These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 16952456

  • 1. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy.
    Tsai LK, Tsai MS, Lin TB, Hwu WL, Li H.
    Neurobiol Dis; 2006 Nov; 24(2):286-95. PubMed ID: 16952456
    [Abstract] [Full Text] [Related]

  • 2. Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.
    El-Khodor BF, Edgar N, Chen A, Winberg ML, Joyce C, Brunner D, Suárez-Fariñas M, Heyes MP.
    Exp Neurol; 2008 Jul; 212(1):29-43. PubMed ID: 18455159
    [Abstract] [Full Text] [Related]

  • 3. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy.
    Hahnen E, Eyüpoglu IY, Brichta L, Haastert K, Tränkle C, Siebzehnrübl FA, Riessland M, Hölker I, Claus P, Romstöck J, Buslei R, Wirth B, Blümcke I.
    J Neurochem; 2006 Jul; 98(1):193-202. PubMed ID: 16805808
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Understanding motoneurone development explains spinal muscular atrophy.
    Vrbová G.
    Arch Ital Biol; 2007 Nov; 145(3-4):325-35. PubMed ID: 18075125
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, Keyvan M, Pai G, Mishra R, Haraldsson M, Andresson T, Bragason G, Thosteinsdottir M, Bjornsson JM, Coovert DD, Burghes AH, Gurney ME, Singh J.
    J Med Chem; 2008 Feb 14; 51(3):449-69. PubMed ID: 18205293
    [Abstract] [Full Text] [Related]

  • 14. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
    Sinn DI, Kim SJ, Chu K, Jung KH, Lee ST, Song EC, Kim JM, Park DK, Kun Lee S, Kim M, Roh JK.
    Neurobiol Dis; 2007 May 14; 26(2):464-72. PubMed ID: 17398106
    [Abstract] [Full Text] [Related]

  • 15. Ciliary neurotrophic factor-induced sprouting preserves motor function in a mouse model of mild spinal muscular atrophy.
    Simon CM, Jablonka S, Ruiz R, Tabares L, Sendtner M.
    Hum Mol Genet; 2010 Mar 15; 19(6):973-86. PubMed ID: 20022887
    [Abstract] [Full Text] [Related]

  • 16. Challenges and opportunities in clinical trials for spinal muscular atrophy.
    Hirtz D, Iannaccone S, Heemskerk J, Gwinn-Hardy K, Moxley R, Rowland LP.
    Neurology; 2005 Nov 08; 65(9):1352-7. PubMed ID: 16275820
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy.
    Rindt H, Buckley DM, Vale SM, Krogman M, Rose FF, Garcia ML, Lorson CL.
    Neuromuscul Disord; 2012 Mar 08; 22(3):277-85. PubMed ID: 22079083
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.